The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks).
The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection.
No follow up visits are required for this study.
≥ 18 years old
Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis
Under the care of Royal Papworth Hospital
Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ²
Patients unable to provide written informed consent
Lung transplant recipients or on lung transplant waiting list
Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure
Patients unwilling to consent to their link anonymised data from home monitoring being used for research
Patients admitted under the specialist care of Royal Papworth Hospital Foundation Trust, Cambridge, UK
Cohort
Prospective
Non-Interventional Study
Other interventionnon-interventional
The change in physiological parameter measure such as heart rate (sensor dependant) between the start and end of intravenous antibiotics for acute pulmonary exacerbation.
mean of parameter (e.g. heart rate) taken from first 2 days of IV antibiotics vs the last 2 days of antibiotics will be compared
Click on the lead sponsor to view all of their trials.
Papworth Hospital NHS Foundation Trust
Lead sponsor
LifeArc
Collaborator
University of Cambridge
Collaborator
Department of Health, United Kingdom
Collaborator
National Institute for Health Research, United Kingdom
Collaborator
